Vesica AI, a promising medical startup company, has been selected as the winner of the inaugural Olympus Asia Pacific Innovation Program (OAIP). Vesica AI was chosen from a field of four finalists for its innovative AI-based clinical support system that supports and enhances the early detection of bladder cancer through the cystoscopy procedure. Vesica AI is the result of a collaboration between the University of Tsukuba Hospital in the Ibaraki-prefecture, Japan, and the National Institute of Advanced Industrial Science and Technology (AIST), a Japanese public agency promoting scientific development.
Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, partnered with MedTech Innovator Asia Pacific, the industry’s largest healthcare accelerator, to launch and facilitate the OAIP which ran throughout 2023. The program invited visionary startups with a connection to the Asia Pacific region to participate in the OAIP by submitting technologies that play a meaningful role in the advancement of minimally invasive care and new ways to detect, monitor, and treat conditions and diseases.
Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024
As the winning innovator, Vesica AI will receive grant funding of $75,000 as well as an exclusive mentorship program with key thought leaders from Olympus. The mentorship program will connect Vesica AI with experts from Olympus in meaningful ways that aim to support the future success of the company.
Recommended AI News: Avaya Helps UK and Ireland Enterprises Deliver AI-Powered Innovation Without Disruption
“All our four finalists showcased technology that could potentially revolutionize their respective fields in healthcare and improve patient outcomes. They presented strongly, and through this process, we are delighted to have selected Vesica AI as the inaugural winner of the Olympus Asia Pacific Innovation program. We are excited to help the Vesica AI team and the UroAI platform as we seek to elevate the standard of care in bladder cancer diagnosis,” said Felicia Chung, Business Development Head at Olympus Corporation Asia Pacific.
“This recognition is a testament to the hard work and dedication of our team, we strongly believe this mentorship program will be transformational for us in refining our business model, laser-focusing our commercialization and research and development efforts, and accelerating our fundraising and strategic collaboration plans,” said Albert Liu, Chief Executive Officer Vesica AI, and Charles Zahl, Chief Operating Officer Vesica AI, in a combined statement.
Recommended AI News: Sprinklr Empowers Businesses to Deploy and Scale Generative AI-powered Conversational Bots
Marc Radatt, CEO of Olympus Corporation Asia Pacific, added: “We came away very impressed with Vesica AI’s innovative technology and the potential it has to transform the early detection of bladder cancer through cystoscopy as well as to make a real difference in the lives of patients across the Asia Pacific region and the world. As inaugural winners, we look forward to working with their talented team.
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.